Literature DB >> 3709619

Pharmacokinetic and pharmacodynamic studies following the intravenous and oral administration of the antiparkinsonian drug biperiden to normal subjects.

R Grimaldi, E Perucca, G Ruberto, C Gelmi, F Trimarchi, M Hollmann, A Crema.   

Abstract

The pharmacokinetics and pharmacodynamics (changes in pupil size and salivary flow) of biperiden following a single oral and intravenous dose were investigated in six normal subjects. After the injection plasma concentrations declined biphasically, with half-times of 1.5 h for the rapid phase and 24 h for the terminal phase. Clearance and apparent volume of distribution were high (12 ml X min-1 X kg-1 and 24 l X kg-1 respectively). Absorption was rapid but the systemic availability was incomplete (33%), probably due to first-pass metabolism. Central nervous system (CNS) adverse effects and changes in pupil size were observed after both routes of administration while salivary flow was affected only by the injection.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3709619     DOI: 10.1007/bf00615970

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  5 in total

1.  [Metabolism of antiparkinson drugs. An example of competitive hydroxylation].

Authors:  B Stock; G Spiteller
Journal:  Arzneimittelforschung       Date:  1979

2.  Pharmacokinetics of oxiracetam following intravenous and oral administration in healthy volunteers.

Authors:  E Perucca; A Albrici; G Gatti; R Spalluto; M Visconti; A Crema
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1984 Jul-Sep       Impact factor: 2.441

3.  Biperiden effects and plasma levels in volunteers.

Authors:  M Hollmann; E Brode; G Greger; H Müller-Peltzer; N Wetzelsberger
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

4.  Capillary gas chromatographic determination of biperiden in human plasma.

Authors:  T Le Bris; E Brode
Journal:  Arzneimittelforschung       Date:  1985

5.  Reduction of oral bioavailability of lignocaine by induction of first pass metabolism in epileptic patients.

Authors:  E Perucca; A Richens
Journal:  Br J Clin Pharmacol       Date:  1979-07       Impact factor: 4.335

  5 in total
  9 in total

1.  Computational models to assign biopharmaceutics drug disposition classification from molecular structure.

Authors:  Akash Khandelwal; Praveen M Bahadduri; Cheng Chang; James E Polli; Peter W Swaan; Sean Ekins
Journal:  Pharm Res       Date:  2007-09-11       Impact factor: 4.200

Review 2.  Clinical pharmacokinetics of anti-parkinsonian drugs.

Authors:  J M Cedarbaum
Journal:  Clin Pharmacokinet       Date:  1987-09       Impact factor: 6.447

Review 3.  Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease.

Authors:  Dirk Deleu; Margaret G Northway; Yolande Hanssens
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

4.  Interaction study between remoxipride and biperiden.

Authors:  W Yisak; L Farde; C von Bahr; L B Nilsson; G Fredriksson; S Ogenstad
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

Review 5.  Pharmacokinetic optimisation in the treatment of Parkinson's disease.

Authors:  M Contin; R Riva; F Albani; A Baruzzi
Journal:  Clin Pharmacokinet       Date:  1996-06       Impact factor: 6.447

6.  Mechanistic approaches to volume of distribution predictions: understanding the processes.

Authors:  Trudy Rodgers; Malcolm Rowland
Journal:  Pharm Res       Date:  2007-03-20       Impact factor: 4.580

7.  The muscarinic M1 receptor modulates associative learning and memory in psychotic disorders.

Authors:  Geor Bakker; Claudia Vingerhoets; Oswald J N Bloemen; Barbara J Sahakian; Jan Booij; Matthan W A Caan; Thérèse A M J van Amelsvoort
Journal:  Neuroimage Clin       Date:  2020-05-26       Impact factor: 4.881

8.  Performance of conventional pigs and Göttingen miniature pigs in a spatial holeboard task: effects of the putative muscarinic cognition impairer Biperiden.

Authors:  Elise Gieling; Welmoed Wehkamp; Remco Willigenburg; Rebecca E Nordquist; Niels-Christian Ganderup; Franz Josef van der Staay
Journal:  Behav Brain Funct       Date:  2013-01-10       Impact factor: 3.759

9.  Biperiden Challenge Model in Healthy Elderly as Proof-of-Pharmacology Tool: A Randomized, Placebo-Controlled Trial.

Authors:  Charlotte Bakker; Michiel J van Esdonk; Rik F E Stuurman; Laura G J M Borghans; Marieke L de Kam; Joop M A van Gerven; Geert Jan Groeneveld
Journal:  J Clin Pharmacol       Date:  2021-07-29       Impact factor: 3.126

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.